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Abstract
Inducible co-stimulator (ICOS) is a member of CD28/Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) family and broadly
expressed in activated CD4+ T cells and induced regulatory CD4+ T cells (CD4+ iTreg). ICOS-related signal pathway
could be activated by the interaction between ICOS and its ligand (ICOSL). In our previous work, we established a
cost-effective system to generate a novel human allo-antigen specific CD4hi Treg by co-culturing their naïve
precursors with allogeneic CD40-activated B cells in vitro. Here we investigate the role of ICOS in the generation and
function of CD4hi Treg by interrupting ICOS-ICOSL interaction with ICOS-Ig. It is found that blockade of ICOS-ICOSL
interaction impairs the induction and expansion of CD4hi Treg induced by allogeneic CD40-activated B cells. More
importantly, CD4hi Treg induced with the addition of ICOS-Ig exhibits decreased suppressive capacity on alloantigen-
specific responses. Dysfunction of CD4hi Treg induced with ICOS-Ig is accompanied with its decreased exocytosis
and surface CTLA-4 expression. Through inhibiting endocytosis with E64 and pepstatin A, surface CTLA-4
expression and suppressive functions of induced CD4hi Treg could be partly reversed. Conclusively, our results
demonstrate the beneficial role of ICOS-ICOSL signal pathway in the generation and function of CD4hi Treg and
uncover a novel relationship between ICOS and CTLA-4.
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Introduction
Inducible costimulator (ICOS), a member of CD28 and
cytotoxic T lymphocyte antigen 4 (CTLA-4) cell surface
receptor family, is absent in naïve human T cells but could be
induced in activated human T cells [1]. Expressions of ICOS
exert distinct impacts on the outcomes of CD4+ T cell-mediated
immune responses corresponding to different immunological
context. The effects of ICOS on the functions of T cell are
mainly initiated by the interaction between ICOS and its ligand
(B7 related protein 1, B7RP1 or ICOSL), which is generally
expressed on diverse antigen presenting cells (APC) [2]. ICOS-
related signal plays important roles in many T cell-mediated
disease models, such as inflammation [3], anti-viral immune
responses [4], anti-tumor immune responses [5], allogeneic
grafts rejection [6,7], wound healing [8], and thus representing
a potential target of treatment [9]. However, the roles of ICOS-
ICOSL interaction in human immune system are still inclusive.
The roles of ICOS in T cell-mediated immune responses are
multiplex. In addition to its roles in the proliferation and
migration of T cells in mice [10,11], ICOS was also found to be
involved in differentiation of murine CD4+ T cell recently. Under
specific conditions, ICOS could either promotes Th2 cell
differentiation [12] or mediate Th1-like responses [13]. The role
of ICOS in Th17 cell differentiation remains controversial [14],
although its expression in T cells was shown to attenuate
Th17-related inflammation in an experimental autoimmune
encephalitis (EAE) model [15]. More recently, ICOS was also
identified as a critical marker of follicular T cells (Tfh), and its
interaction with ICOSL on B cells was necessary for the
development and antibody production of murine B cells [16].
Actually, the effect of ICOS on humoral immunity has been
confirmed in common variable immunodeficiency patients [17].
CD4+ regulatory T cells (CD4+ Treg) represent for a small
population in human peripheral lymphocytes and exhibit
suppressive capability on distinct immune responses. CD25,
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Foxp3 and CTLA-4 are mostly accepted markers for CD4+
Treg, whereas the roles of ICOS in CD4+ Treg remain to be
clarified. In murine system, ICOS was found to be an important
marker of induced CD4+ Treg [18,19] and plays indispensible
roles in induction and maintenance of immune tolerance
besides its function in regulating the differentiation of effector T
cells [20]. Moreover, murine CD4+ICOS+ Treg demonstrated
better survival, proliferative, and even suppressive abilities than
their ICOS- analogues [21]. In support to this, ICOS knock-out
NOD mice exhibits dominant defect in their CD4+ Treg [22].
Consistent with its beneficial role in the generation of murine
CD4+ Treg [23-25], the expression of ICOS was recently found
to promote the generation [26,27], drive the activation [28], and
improve the function of human CD4+ Treg [26,29,30]. In clinic,
ICOS+CD4+ Treg has been identified in type I autoimmune
pancreatitis patients and found to help ameliorate the disease
severity [31]. Interestingly, functions of both murine and human
ICOS-related signals in T cells are found to be regulated by
CD28 and CTLA-4 [4,13,29,32], whereas the effect of ICOS-
ICOSL on the expression of CTLA-4 has never been illustrated.
In our previous studies, we established a novel system to
generate alloantigen-specific CD4hi Treg from their naive
precursors by co-culturing them with allogeneic CD40-activated
B cells [33]. In this study, we examined the expression of ICOS
in these induced CD4hi Treg, and investigated the roles of
ICOS-related signals in their generation and functions. It was
found that ICOS-ICOSL promoted the generation of CD4hi Treg
through reducing the apoptosis of CD4+ T cells. More
importantly, the blockade of ICOS-ICOSL by ICOS-Ig during
induction impaired the suppressive capacity of generated CD4hi
Treg. The reduced suppressive capacity of CD4hi Treg was due
to down-regulated expression of its surface CTLA-4, which
might resulted from decreased exocytosis caused by ICOS-Ig.
By inhibiting the endocytosis of CTLA-4 with E64 and pepstatin
A, the function of CD4hi Treg could be partly reversed. Taken
together, our results demonstrate the beneficial roles of ICOS
in the generation of functional human CD4+ Treg and a novel
relationship between ICOS and CTLA-4.
Materials and Methods
Ethics statement
Written consent for the use of buffy coat for research
purposes was obtained from the donors by the Hong Kong Red
Cross Blood Transfusion Services at the time of blood
donation. The use of buffy coat for this experiment was
approved by the Institutional Review Board of the University of
Hong Kong/Hospital Authority Hong Kong West Cluster (IRB
Reference Number: UW 07-390).
Generation of CD40-activated B cells
B cells from PBMCs were stimulated via CD40 using NIH3T3
cells transfected with the human CD40 ligand (t-CD40-L cells)
as described previously [33,34]. Briefly, PBMC were co-
cultured with the lethally irradiated (96Gy) t-CD40-L cells in the
presence of IL-4 (2.0 ng/ml; R&D systems, Minneapolis, MN,
USA) and cyclosporine A (5.5×10-7 M, Sigma-Aldrich, St. Louis,
MO, USA) in IMDM (GIBCO-BRL, Carlsbad, CA, USA)
supplemented with 10% heat-inactivated human AB serum, 50
µg/ml transferrin (Boehringer Mannheim, Indianapolis, IN,
USA), 5.0 µg/ml insulin (Sigma-Aldrich, St. Louis, MO, USA),
and 15.0 µg/ml gentamicin (Life Technologies, USA) at 37°C in
5% CO2. After 14 days of co-culture, more than 95% of the
viable suspended cells are routinely CD19 positive. For future
use, B cells were cryopreserved in 10% DMSO FBS. For co-
culture with CD4+ T cells, CD40-activated B cells were always
Ficoll-density centrifuged followed by washing with PBS twice
to remove nonviable cells including remaining t-CD40-L cells.
CD4+ T cell isolation
Human naïve CD4+ T cells were isolated from healthy donor
PBMC by negative selection using a naïve CD4+ T cell isolation
kit (depletes CD8, CD14, CD16, CD19, CD25, CD36, CD56,
CD123, TCRγ/δ, CD235a, and CD45RO) (Miltenyi Biotec, CA,
USA). The purity of selected cells was routinely more than 98%
as determined by flow cytometric analysis.
Induction and expansion of CD4hi Treg
Freshly purified human naïve CD4+CD45RO-CD25- T cells
were co-cultured with allogeneic CD40-activated B cells at a T
cell: B cell ratio of 10:1 in RPMI 1640 medium supplemented
with 10% heat-inactivated human AB serum. In repeated
stimulation experiments, allogeneic CD40-activated B cells
were added every 6 days of culture. Functional and
phenotypical hallmarks of the induced and expanded T cells
were examined at indicated time of culture. The expansion of
viable cells was determined by counting aliquots of cells that
excluded trypan blue dye.
Flow cytometric assays
Cells were analyzed by flow cytometry using a FACSAria
(BD Biosciences, CA, USA) after staining with the following
fluorescence-conjugated mAb (all from BD-Biosciences unless
otherwise specified): anti-human CD4-Alexa-405, anti-human
CD25-APC, anti-human CD27-PE, anti-human CD44-PE, anti-
human CD45RO-APC, anti-human CD63-FITC, anti-human
CD107a-FITC, anti-human glucocorticoid induced TNF
receptor-related protein (GITR)-PE, anti-human CTLA-4-PE,
anti-human ICOSL-PE, and anti-human ICOS-PE. Intracellular
staining was performed after cell fixation and permeabilization
reagents (Fix and Perm) (BD Biosciences, CA, USA). The
following anti-cytokine mAbs were used: anti-human IL-10-PE
(R&D, CA, USA), anti-human TGF-β-PE (IQ Products,
Netherlands) and their isotype-matched controls of irrelevant
specificity. Human Foxp3 staining kit (eBiosciences, CA, USA)
was used for Foxp3 staining.
Cell death and proliferation assays
Percentage of apoptotic and proliferative cells in the co-
culture was determined by propidium iodide (PI) (Invitrogen Life
Technologies, CA, USA) and carboxyfluorescein succinimidyl
ester (CFSE) (Sigma) correspondingly as described previously
[34]. For PI staining, cells were stained with PI for 15 minutes
and analyzed by flow cytometry for PI-positive (dead) cells
gating on the cell type of interest. For CFSE staining, 22 µl of
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0.05mM CFSE solution were added into 1 ml of cells
(concentration of 5×106 cells/ml) and incubate at 37°C for 5
min. Stained cells were harvested at indicated time points and
the levels of CFSE were analyzed using FACS Aria-II (BD) and
Flowjo software (Tree Star Inc.).
Mixed lymphocyte reaction (MLR) assays
The suppressive capacity of CD40-activated B cell-induced
CD4hi Treg was examined in a MLR system as described
before [33,34]. CD4hi Treg was sorted by a FACSAria after 9
days of co-culturing naive CD4+ CD25- T cells and allogeneic
CD40-acitvated B cells. The purity of sorted cells was routinely
more than 95%. The sorted CD4hi Treg referred as “regulator”
were titrated and added at the start of MLR assays, consisting
of a total of 5×104 responder CD4+CD25- T cells from the same
donor of CD4+ regulator cells and 5×104 γ-irradiated target
PBMC from the donor of CD40-activated B cells or unrelated
donor. Proliferation of responder was analyzed by [3H]-
thymidine incorporation assay. [3H]-thymidine incorporation
was expressed as the mean ± SEM counts per 1 min of 4 to 6
measurements.
Blocking assays
Blocking studies were performed with a fusion protein ICOS-
Ig (a gift from Anthony Coyle, Millennium Pharmaceutics), and
the neutralization mAbs directly against CTLA-4 (10µg/ml,
Ancell, USA) in conjunction with their relevant isotype controls.
In some experiments, protease inhibitor 30µM of E64 and
100μM of pepstatin A (Calbiochem, Germany) were separately
added at the initiation of co-culture and supplemented with the
replacement of medium every three days.
Statistical analysis
Data are means ± SEM. The differences in different
treatment groups were analyzed by unpaired two-tailed
Student’s t test following One-Way ANOVA test. Graphs and
statistical analyses were performed with the use of Prism 5.0
for Windows software (GraphPad Software, San Diego, CA,
USA). P values of 0.05 or less were considered significant.
Results
Expression of ICOS in CD4hi Treg induced by allogeneic
B cells
We firstly examined the expression of ICOS and ICOS-L in
allogeneic CD40-activated B cells and T cells. As shown in
Figure 1A, CD40-activated B cells expressed ICOS-L but did
not express ICOS. Consistent with our previous results [33,34],
a novel CD4hiCD25+ T cell subpopulation was induced from
naive CD4+CD45RO-CD25- T cells after 6 days of co-culture
with allogeneic CD40-activated B cells (Figure 1B). This
CD4hiCD25+ T cell subpopulation expressed high level of
Foxp3 (Figure 1C) and thus was refered as CD4hi Treg.
Although ICOS expression was absent in naive CD4+CD25- T
cells, the induced CD4hi Treg expressed high levels of ICOS
after 6 days of co-culture (Figure 1C). These results suggest
ICOS-ICOSL might be involved in the interaction between T
and B cells.
Blockade of ICOS-ICOSL impairs the generation and
survival of CD4hi Treg
We next investigated the role of ICOS-ICOSL in the
generation of CD4hi Treg induced by CD40-activated B cells.
The blockade of the ICOS-ICOSL interaction by ICOS-Ig fusion
protein inhibited the generation of CD4hi Treg in a dose
dependent manner, as shown by the decreases in the absolute
numbers of total CD4+ and CD4hi Treg after 6 days of co-
culture (Figure 2A and 2B). To understand the mechanisms
underlying the decrease in the generation of Treg by blocking
ICOS-ICOS-L interaction, we further examined the effect of
ICOS-Ig on survival of CD4+ T cells during co-culture. As
shown in Figure 2C, the treatment of ICOS-Ig significantly
increased the cell death of CD4hi Treg but did not affect the
survival of CD4+CD25- T cells. These results indicated that the
ICOS-ICOSL interaction improves the generation and survival
of CD4hi Treg. Since IL-2 is an important down-stream
molecule of ICOS-related signal pathway [1] while endogenous
IL-2 secreted by CD40-activated B cells play cardinal role
during generation of CD4hi Treg [33], we then added IL-2 into
co-culture to investigate whether the decreased generation of
CD4hi Treg could be reversed by exgenous IL-2. As shown in
Figure 2D, the addition of IL-2 promoted the expansion of CD4hi
Treg while rescued their death induced by ICOS-Ig, which
confirmed the crucial role of IL-2 in signal transferred by ICOS-
ICOSL.
ICOS is not required for CD4hi Treg effector function To
clarify whether the blockade of ICOS-ICOSL during the initial
co-culture could affect the functions of induced CD4hi Treg, we
added ICOS-Ig and its control Ig (IC) at the start of the co-
culture of naïve CD4+CD45RO-CD25- T cells with allogeneic
CD40-activated B cells. Consistent with our previous report
[33], CD4hi Treg induced by allogeneic CD40-activated B cells
were alloantigen-specific Treg, since they only suppressed the
original target alloantigen-induced proliferation but showed no
effects on third-party alloantigen-induced proliferation (Figure
3A). The alloantigen-specific suppressive ability of CD4hi Treg
generated in the co-culture supplemented with ICOS-Ig
decreased significantly compared to the control group (Figure
3A). We further added ICOS-Ig or control Ig (IC) directly into
MLR system to illustrate whether ICOS participate into the
suppression mediated by innocent CD4hi Treg. However, the
blockade of ICOS-ICOSL did not reverse CD4hi Treg-mediated
suppression on MLR (Figure 3B). These data suggest that
ICOS-ICOSL plays a critical role in the generation of functional
CD4hi Treg but is not involved in effect phase of its
suppression.
Blockade of ICOS-ICOSL decreases Foxp3 and surface
CTLA-4 expressions in CD4hi Treg
To explore the mechanisms underlying the effects of ICOS
on the generation of functional CD4hi Treg, we firstly compared
the expression levels of CD4, CD25, and Foxp3 in CD4hi Treg
induced by CD40-activated B cells with the addition of ICOS-Ig
to those of control group. As shown in Figure 4A, blockade of
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ICOS-ICOSL decreased the expressions of CD4 and Foxp3,
but did not affect CD25 expression in induced CD4hi Treg. We
then examined the expressions of T cell activation markers
(CD27, CD44, and CD45RO), and found there were no
differences of the expression for these activation makers in
CD4hi Treg between groups treated with ICOS-Ig or its control
Ig (IC) (Figure 4B), suggesting these activation molecules are
not involved in the ICOS-mediated CD4hi Treg generation. The
involvements of GITR, IL-10, and TGF-β in the impaired
suppressive capacity of CD4hi Treg caused by ICOS-Ig were
also excluded because no difference of these molecules was
found in CD4hi Treg between groups treated with ICOS-Ig
versus its isotype control Ig (Figure 4B). Interestingly, surface
CTLA-4 expression in CD4hi Treg generated in presence of
ICOS-Ig decreased significantly compared to the control,
whereas there was no difference in whole-cell CTLA-4
expression determined by antibody staining after fixation and
permeabilization (Figure 4B). These data indicated that
blockade of ICOS-ICOS interaction decreased Foxp3 and
surface CTLA-4 expressions in CD4hi Treg, suggesting the
reduced Foxp3 and surface CTLA-4 expressions may
contribute to the impaired suppressive capacity of CD4hi Treg
caused by blockade of ICOS-ICOSL.
Figure 1.  ICOS expressions in CD40-activated B cells and CD4+ T cell subsets.  (A) Expressions of ICOS and ICOSL in CD40-
activated B cells. (B-C) Naïve CD4+CD25- T cells isolated from normal PBMC were co-cultured with allogeneic CD40-activated B
cells at a ratio of 10:1 without exogenous cytokines for 6 days, the expressions of CD4, CD25 (B) and Foxp3, ICOS (C) in CD4+ T
cell populations were determined by flow cytometry. The data represent for 20 independent experiments.
doi: 10.1371/journal.pone.0082203.g001
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Generation of functional CD4hi Treg is dependent on its
surface expression of CTLA-4
To confirm the benefit role of surface CTLA-4 expression in
the generation of CD4hi Treg, anti-CTLA-4 neutralizing mAb,
which block the interaction between surface CTLA-4 and its
ligand CD80/CD86, or its isotype control (IC) were added into
the co-culture of naïve CD4+CD45RO-CD25- T cells with
allogeneic CD40-activated B cells at the start of incubation.
Similar to ICOS-Ig, CTLA-4 neutralizing mAb down-regulated
the expressions of CD4 and Foxp3 but did not affect the
expression of CD25 or ICOS in the induced CD4hi Treg (Figure
5A). Meanwhile, CTLA-4 neutralizing mAb significantly
decreased the absolute number of the induced CD4hi Treg
(Figure 5B). Most importantly, the treatment of CTLA-4
neutralizing mAb abolished most of the alloantigen-specific
suppression of induced CD4hi Treg (Figure 5C). We also
detected the effects of conjunction of anti-CTLA-4 and ICOS-Ig
on the generation and function of CD4hi Treg but found there
was no significant difference in the outcome between ICOS-Ig
+anti-CTLA-4 and anti-CTLA-4 alone group, (data not shown),
suggesting that the function of ICOS was mainly dependent on
the surface expression of CTLA-4. The indispensable role of
CTLA-4 during the generation of functional CD4hi Treg
demonstrated here strongly suggests that surface CTLA-4
expression play a critical role in ICOS-mediated CD4hi Treg
generation.
Figure 2.  ICOS-ICOSL mediates the generation of CD4hi Treg.  Naïve CD4+CD25- T cells were co-cultured with allogeneic
CD40-activated B cells at a ratio of 10:1 for indicated time. ICOS-Ig and its relevant isotype controls (IC) were added at the final
concentration of 5µg/ml or 50µg/ml since the initiation of co-culture and supplemented with replacement of medium every 3 days.
The absolute number of total CD4+ T cells (A) and CD4hi Treg (B) was examined. The percentage of PI+ cells in CD4+CD25- and
CD4hi Treg on day 9 post co-culture (C) was examined as described in “cell death and proliferation assays”. Data for 4 different
experiments are shown here and the 2-tailed unpaired Student t tests were used for comparing between group with ICOS-Ig and IC
at indicated time. (n=4, *P<0.05, **P<0.01) (D) Exogenous IL-2 on proliferation and apoptosis of CD4hi Treg. 50µg/ml ICOS-Ig was
added into the co-culture with or without 250IU/ml recombinant human IL-2 and suppleted with replacement of medium every 3
days. The proliferation and apoptosis of CD4hi Treg were determined by CFSE and PI staining correspondingly on day 9 post co-
culture. Data represent for 3 independent experiments.
doi: 10.1371/journal.pone.0082203.g002
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ICOS regulates the dynamic transfer of CTLA-4
between cell surface and cytoplasm
Finally, we investigated the underlying mechanisms of the
decreased expression of surface CTLA-4 in CD4hi Treg induced
with the addition of ICOS-Ig. Since total CTLA-4 expression
was innocent with ICOS-Ig treatment, we supposed that the
decreased surface CTLA-4 might resulted from its impaired
transport between surface and cytoplasm. This hypothesis was
supported by the decrease of exocytosis as evidenced by the
Figure 3.  ICOS is not required for CD4hi Treg effector
function.  CD4+CD25– cells (5×104, responder, R) and γ-
irradiated allogeneic PBMC (5×104, stimulator, S) were co-
cultured as described in “MLR assays”. (A) CD4hi Treg was
sorted on day 9 from the co-culture supplemented with 50µg/ml
ICOS-Ig or its relevant isotype controls (IC). The sorted cells
were serially diluted and added into MLR as regulators. (B)
Innocent CD4hi Treg were used as regulators, and ICOS-Ig or
IC was added respectively on the start of the MLR co-culture at
the final concentration of 50µg/ml. On day 3 after co-culture,
proliferation of responder was examined as described. The
data represent for 4 independent experiments and the 2-tailed
unpaired Student t tests were used for comparing between
groups with ICOS-Ig and IC. (n=4, *P<0.05, **P<0.01).
doi: 10.1371/journal.pone.0082203.g003
reduced CD107a and CD63 expressions in CD4hi Treg after
ICOS-Ig treatment (Figure 6A). To restore the surface CTLA-4
expression in CD4hi Treg, endocytosis inhibitors E64 and
pepstatin A (EP) were added at the start of co-culture of naïve
CD4+CD45RO-CD25- T cells with allogeneic CD40-activated B
cells. As shown in Figure 6B, decreased surface CTLA-4
expression caused by ICOS-Ig was reversed by the addition of
protease inhibitor EP. Consistent with that, the suppressive
capacity of CD4hi Treg induced in the presence of ICOS-Ig was
improved by EP treatment. These results indicate the
decreased surface CTLA-4 expression and reduced
suppressive capacity in CD4hi Treg caused by ICOS-Ig were
related to the impairment of CTLA-4 transport from cytoplasm
to membrane.
Discussion
As a member of CD28 and CTLA-4 costimulator family,
ICOS can be induced in activated T cells and mediates diverse
immune reactions [1], but their roles in the generation of Treg,
especially human Treg are still on debate [26,29,30]. We
previously established a system to generate alloantigen-
specific CD4hi Treg from their naive precursors by co-culture
with allogeneic CD40-activated B cells in vitro. However, the
roles of co-stimulators in the generation of this induced Treg
remain to be clarified. In this study, we demonstrated that
ICOS-ICOSL was essential for the generation of CD4hi Treg.
More importantly, ICOS-related signal determined the
generation of functional CD4hi Treg through regulating the
transport of CTLA-4 in CD4hi Treg.
ICOS-ICOSL interaction is involved in human T cell
activation and tolerance, and these functions were partly
dependent on the induction of endogenous IL-2 [1,35]. Here we
found that blockade of ICOS-ICOSL resulted in the decreased
generation of CD4hi Treg (Figure 2B), which was partly caused
by the increased cell apoptosis (Figure 2C). Consistent with
that, our previous study demonstrated that IL-2 secreted from
CD40-activated B cells might play an important role during the
generation of CD4hi Treg [33]. Although it has been suggested
that the response of CD4+ T cells to IL-2 could be limited
because of low expression level of CD122 [3], high CD25
expression level of induced CD4hi Treg (Figure 1) might
compensate for this mechanism and make IL-2 indispensable
in our system. The fact that ICOS+ CD4+ Treg was more
sensitive to IL-2 than their ICOS- analogues also strengthen the
importance of IL-2 in the generation of CD4hi Treg [24]. This
hypothesis was supported by the facts that addition of
exogenous human IL-2 suppressed apoptosis and restored the
proliferation of CD4hi Treg caused by ICOS-Ig (Figure 2D).
It was found that suppressive capacity of induced CD4hi Treg
was also impaired by blockade of ICOS-ICOSL interaction
during the generation of CD4hi Treg (Figure 3A). Meanwhile,
the reduced suppressive ability of CD4hi Treg was found to be
accompanied with the decreased expression levels of CD4,
Foxp3 and surface CTLA-4 (Figure 4A and 4B). These results
were consistent with the previous studies [33,36], in which
Foxp3 and CTLA-4 were confirmed to be vital for the
suppression mediated by CD4+ Treg. However, the effect of
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ICOS-ICOSL was only identified during the generation of CD4hi
Treg, but not directly involved in CD4hi Treg-mediated
suppression on allo-responses (Figure 3B).
CTLA-4 is a critical inhibitory molecule competing for CD80/
CD86 with CD28 [37,38], and plays an essential role in Treg-
mediated suppression both in vivo and in vitro [39-41]. Both
CTLA-4 and ICOS are important co-stimulatory molecules [42],
but the interaction between these two pathways is still unclear.
Although blockade of CTLA-4 was found to promote the
expansion of T cells mediated by stimulating intrinsic
expression of ICOS [43,44], its effect on ICOS expression here
was indispensible because of high ICOS expression in CD4hi
Treg (Figure 5A). Importantly, it has never been reported
whether ICOS could regulate the expression of CTLA-4 in
Figure 4.  Blockade of ICOS-ICOSL affects the expressions of CD4hi Treg markers.  Naïve CD4+CD25- T cells were co-cultured
with allogeneic CD40-activated B cells at a ratio of 10:1 with the supplement of 50µg/ml ICOS-Ig or its relevant isotype controls (IC)
for 9 days. (A) Expressions of CD4, CD25 (up panel) and Foxp3 (bottom panel) in CD4+CD25- T cells and CD4hi Treg on day 9 post
co-culture. (B) Expressions of T cell activation markers CD27, CD44, CD45RO (up panel), Treg-related markers GITR, surface
CTLA-4, whole-cell CTLA-4 (middle panel), intracellular inhibitory cytokines IL-10 and TGF-β (bottom panel) in CD4+CD25- T cells
and CD4hi Treg on day 9 post co-culture. Data represent for 4 different experiments are shown.
doi: 10.1371/journal.pone.0082203.g004
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Figure 5.  Surface CTLA-4 mediates the generation of
functional CD4hi Treg.  Naïve CD4+CD25- T cells were co-
cultured with allogeneic CD40-activated B cells at a ratio of
10:1 in the presence of 10µg/ml CTLA-4 neutralizing mAb or its
isotype control (IC). (A) Expressions of CD4, CD25 (up panel)
and Foxp3, ICOS (bottom panel) in CD4+CD25- and CD4hi
subsets from different treatment groups on day 6 post co-
culture. (B) The absolute number of total CD4+ T cells (left
panel) and CD4hi Treg (right panel) from different treatment
groups during 9 days. (C) Antigen-specific inhibition mediated
by CD4hi Treg from different treatment groups. CD4+CD25–
cells (5×104, responder, R) and γ-irradiated allogeneic PBMC
(5×104, stimulator, S) were co-cultured while CD4hi Treg from
different groups were sorted on day 6 post co-culture and
added into MLR system at different concentration. 3 days later,
proliferation of responder was determined as described in
“MLR assays”. Results shown here are representative of 4
independent experiments (n=4, *P<0.05, **P<0.01).
doi: 10.1371/journal.pone.0082203.g005
reverse. Here we for the first time demonstrated that blockade
of ICOS-ICOSL interaction caused decreased surface CTLA-4
expression in CD4hi Treg without influencing its whole-cell
expression level (Figure 4B). Generally, CTLA-4 is expressed
on cell surface transiently and then recycled readily through
endocytosis initiated by the attachment of adapter protein 2
(AP-2) on its cytoplasmic tail [32]. However, the interaction of
AP-2 with CTLA-4 could be replaced by activated
phosphatidylinositol 3-kinase (PI3K), which could result in
decreased endocytosis of CTLA-4 [45,46]. Since surface
CTLA-4 and ICOS generally gathered around activated TCR,
PI3K recruited to ICOS might compete with AP-2 on the link
locus of CTLA-4 and thus protect CTLA-4 from endocytosis.
This hypothesis was partly supported by the reverse of
decreased surface CTLA-4 expression and reduced
suppressive capacity in CD4hi Treg caused by ICOS-Ig with the
treatment of endocytosis-related protease inhibitors EP (Figure
6B). On the other side, cytoplasm CTLA-4 was reported to
localize in lysosome or lysosome-related organelles (LRO), and
exported back to surface by exocytosis [47,48]. Here we also
found that surface expression levels of two lysosome markers
CD107a and CD63 decreased accompanied with CTLA-4 with
the treatment of ICOS-Ig (Figure 6A), which suggested that
blockade of ICOS-ICOSL reduced exocytosis as well. Our
results exhibited a novel relationship between CTLA-4 and
ICOS through molecule transport between cell membrane and
cytoplasm, which might be generally involved in self-regulation
of CD4+ T cells generally and deserve further investigation.
In addition to CTLA-4, Foxp3 is also regarded as a
characteristic marker of Treg, and the expression level of
Foxp3 might represent for the suppressive capacity of Treg
[36]. Although there have been several reports suggesting that
the expression of Foxp3 can control the expression of CTLA-4
in Treg [36,49,50], the influences of CTLA-4 on the expression
of Foxp3 has never been reported. Here we found that, similar
to treatment with ICOS-Ig, blockade of CTLA-4 decreased the
expressions of CD4 and Foxp3 but not CD25 (Figure 5A). More
importantly, the decreased expression of Foxp3 was
accompanied with the impaired suppressive capacity of CD4hi
Treg (Figure 5C). Another interesting point was the
neutralization of CTLA-4 signal impaired only the expansion of
induced CD4hi Treg but did not affect the absolute number of
total CD4+ T cells (Figure 5B), which suggested that CTLA-4
determine the quality rather than quantity of CD4hi Treg.
In summary, our study demonstrated some important effects
of ICOS-related signals in the generation of a novel human
alloantigen-specific CD4hi Treg. Moreover, this investigation
provides some interesting information on the interplay of co-
stimulators and their effects on the expression of Foxp3 and
inhibitory functions of CD4+ Treg, which undoubtedly improve
our understanding in underlying mechanisms of T cell
differentiation and self-regulation, and offer some important
molecular basis for future Treg-based therapy.
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Figure 6.  ICOS regulates the dynamic transfer of CTLA-4 between cell surface and cytoplasm.  (A) The surface expressions
of CD107a (left panel) and CD63 (right panel) on CD4hi Treg were determined by FACS analysis after 9 days of co-culture with
allogenic CD40-activated B cells at a ratio of 10:1 with 50ug/ml of ICOS-Ig or its relevant isotype controls (IC). (B-C) Inhibition of
endocytosis restored the surface CTLA-4 expression and impaired suppressive capacity of CD4hi Treg caused by ICOS-ICOSL
blockade. The surface expression of CLTA-4 in CD4hi Treg (B) were determined by FACS analysis after 9 days of co-culture with
allogenic CD40-activated B cells at a ratio of 10:1 with 50µg/ml of ICOS-Ig or its relevant isotype controls (IC). 30µM of E64 and
100uM of pepstatin A (EP) solved in DMSO were added in the culture for inhibiting endocytosis. Antigen-specific inhibition mediated
by CD4hi Treg sorted on day 6 post co-culture from different treatment group (C) were determined as described in “MLR assays”.
Results shown are representative of four independent experiments (n=4, *P<0.05, n.s. no significant difference).
doi: 10.1371/journal.pone.0082203.g006
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